Literature DB >> 19457933

Correlation of the expression of acrB and the regulatory genes marA, soxS and ramA with antimicrobial resistance in clinical isolates of Klebsiella pneumoniae endemic to New York City.

Simona Bratu1, David Landman, Avrille George, Jerome Salvani, John Quale.   

Abstract

OBJECTIVES: Nosocomial isolates of Klebsiella pneumoniae resistant to all commonly used antimicrobial agents have emerged in many regions of the world. It is unknown if efflux systems contribute to the multidrug resistance phenotype.
METHODS: The expression of genes encoding the efflux pump AcrAB and the global regulators MarA, SoxS and RamA were examined and correlated with antimicrobial resistance.
RESULTS: Twenty isolates belonged to the two important clones representing KPC-possessing strains endemic to our region. Virtually all of these isolates had negligible or absent expression of the genes, and resistance to fluoroquinolones and aminoglycosides could be explained by alternative mechanisms. All of these isolates were susceptible to tigecycline. A group of 14 heterogeneous isolates was also examined. There was a correlation between expression of marA with expression of soxS. Only expression of soxS was significantly correlated with expression of acrB. With a background substitution in GyrA, increased expression of acrB and marA appeared to contribute to fluoroquinolone resistance in some isolates. A correlation was noted between expression of soxS and ramA (but not marA and acrB) and tigecycline MICs. Following in vitro exposure to tigecycline, resistance occurred in association with a marked increase in marA and acrB expression in isolates lacking expression of soxS and ramA.
CONCLUSIONS: While laboratory-derived tigecycline resistance was associated with increased acrB expression, the variation in tigecycline MICs in clinical isolates was associated only with selected regulator genes. It appears that other mechanisms beyond activation of the acrAB system mediate tigecycline resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457933      PMCID: PMC2707265          DOI: 10.1093/jac/dkp186

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

1.  Activation of oxidative stress genes by mutations at the soxQ/cfxB/marA locus of Escherichia coli.

Authors:  J T Greenberg; J H Chou; P A Monach; B Demple
Journal:  J Bacteriol       Date:  1991-07       Impact factor: 3.490

2.  marA, a regulated locus which controls expression of chromosomal multiple antibiotic resistance in Escherichia coli.

Authors:  H Hächler; S P Cohen; S B Levy
Journal:  J Bacteriol       Date:  1991-09       Impact factor: 3.490

3.  Absence of mutations in marRAB or soxRS in acrB-overexpressing fluoroquinolone-resistant clinical and veterinary isolates of Escherichia coli.

Authors:  M A Webber; L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  Differential expression of over 60 chromosomal genes in Escherichia coli by constitutive expression of MarA.

Authors:  T M Barbosa; S B Levy
Journal:  J Bacteriol       Date:  2000-06       Impact factor: 3.490

5.  Role of AcrR and ramA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore.

Authors:  T Schneiders; S G B Amyes; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

6.  Multidrug resistance in Klebsiella pneumoniae: a novel gene, ramA, confers a multidrug resistance phenotype in Escherichia coli.

Authors:  Anthony M George; Ruth M Hall; H W Stokes
Journal:  Microbiology (Reading)       Date:  1995-08       Impact factor: 2.777

7.  Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae.

Authors:  Alexey Ruzin; Frederick W Immermann; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

8.  AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis.

Authors:  Melissa A Visalli; Ellen Murphy; Steven J Projan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey.

Authors:  Ufuk Over Hasdemir; Jacqueline Chevalier; Patrice Nordmann; Jean-Marie Pagès
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  RamA is an alternate activator of the multidrug resistance cascade in Enterobacter aerogenes.

Authors:  Renaud Chollet; Jacqueline Chevalier; Claude Bollet; Jean-Marie Pages; Anne Davin-Regli
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

View more
  30 in total

1.  ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline.

Authors:  M Hentschke; M Wolters; I Sobottka; H Rohde; M Aepfelbacher
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

Review 2.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

3.  Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae.

Authors:  Charles R Dean; David T Barkan; Alun Bermingham; Johanne Blais; Fergal Casey; Anthony Casarez; Richard Colvin; John Fuller; Adriana K Jones; Cindy Li; Sara Lopez; Louis E Metzger; Mina Mostafavi; Ramadevi Prathapam; Dita Rasper; Folkert Reck; Alexey Ruzin; Jacob Shaul; Xiaoyu Shen; Robert L Simmons; Peter Skewes-Cox; Kenneth T Takeoka; Pramila Tamrakar; Tsuyoshi Uehara; Jun-Rong Wei
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

4.  Polymorphic variation in susceptibility and metabolism of triclosan-resistant mutants of Escherichia coli and Klebsiella pneumoniae clinical strains obtained after exposure to biocides and antibiotics.

Authors:  Tânia Curiao; Emmanuela Marchi; Carlo Viti; Marco R Oggioni; Fernando Baquero; José Luis Martinez; Teresa M Coque
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

5.  MarA, SoxS and Rob of Escherichia coli - Global regulators of multidrug resistance, virulence and stress response.

Authors:  Valérie Duval; Ida M Lister
Journal:  Int J Biotechnol Wellness Ind       Date:  2013

Review 6.  Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria.

Authors:  Hiroshi Nikaido; Jean-Marie Pagès
Journal:  FEMS Microbiol Rev       Date:  2011-07-29       Impact factor: 16.408

Review 7.  Tetracycline Antibiotics and Resistance.

Authors:  Trudy H Grossman
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

8.  Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.

Authors:  M Hentschke; M Christner; I Sobottka; M Aepfelbacher; H Rohde
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

9.  IS5 element integration, a novel mechanism for rapid in vivo emergence of tigecycline nonsusceptibility in Klebsiella pneumoniae.

Authors:  Lindsey E Nielsen; Erik C Snesrud; Fatma Onmus-Leone; Yoon I Kwak; Ricardo Avilés; Eric D Steele; Deena E Sutter; Paige E Waterman; Emil P Lesho
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

10.  Effect of transcriptional activators SoxS, RobA, and RamA on expression of multidrug efflux pump AcrAB-TolC in Enterobacter cloacae.

Authors:  Astrid Pérez; Margarita Poza; Jesús Aranda; Cristina Latasa; Francisco Javier Medrano; María Tomás; Antonio Romero; Iñigo Lasa; Germán Bou
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.